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Objective   The aim of this study was to evaluate the costs associated with pre-employment nerve conduction 
testing as a screening tool for carpal tunnel syndrome (CTS) in the workplace.
Methods   We used a Markov decision analysis model to compare the costs associated with a strategy of screen-
ing all prospective employees for CTS and not hiring those with abnormal nerve conduction, versus a strategy 
of not screening for CTS. The variables included in our model included employee turnover rate, the incidence of 
CTS, the prevalence of median nerve conduction abnormalities, the relative risk of developing CTS conferred by 
abnormal nerve conduction screening, the costs of pre-employment screening, and the worker’s compensation 
costs to the employer for each case of CTS. 
Results   In our base case, total employer costs for CTS from the perspective of the employer (cost of screening 
plus costs for workers’ compensation associated with CTS) were higher when screening was used. Median costs 
per employee position over five years were US$503 for the screening strategy versus US$200 for a no-screening 
strategy. A sensitivity analysis showed that a strategy of screening was cost-beneficial from the perspective of 
the employer only under a few circumstances. Using Monte Carlo simulation varying all parameters, we found 
a 30% probability that screening would be cost-beneficial. 
Conclusions   A strategy of pre-employment screening for CTS should be carefully evaluated for yield and 
social consequences before being implemented. Our model suggests such screening is not appropriate for most 
employers.
Key terms   cost–benefit analysis; CTS; economic evaluation; electrodiagnostic study; musculoskeletal disorder; 
MSD; post-offer pre-placement screening.
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The yield and cost–benefit of pre-employment screening 
strategies for occupational diseases are rarely subjected 
to formal analysis (1). We developed a dynamic deci-
sion analytic model to estimate the cost–benefit of pre-
employment nerve conduction testing as a screening tool 
for carpal tunnel syndrome (CTS) in the workplace. CTS 
is a major health concern in certain occupations, result-
ing in frequent time away from work and high workers’ 
compensation costs (2, 3). Pre-employment screening 
with electrodiagnostic studies (EDS) to assess nerve con-
duction has been promoted as a strategy to reduce CTS in 
jobs requiring intensive hand activity. The rationale for 
this practice is that workers with abnormal median nerve 
conduction are at an increased risk of developing CTS, 
so an employer’s overall rate of CTS can be reduced by 
excluding workers with impaired nerve function from 
hand-intensive jobs (4–6). Court decisions in the United 
States support the practice of excluding workers from 
jobs based on the results of nerve conduction testing (7). 
A number of employers in the USA now routinely test 
new workers with EDS and make hiring decisions based 
on the results. However, this practice is controversial (8, 
9), and there has been little evaluation of its diagnostic 
test yield or cost– benefit outcome.
In the only formal cost–benefit evaluation of post-
offer, pre-placement screening for CTS, Franzblau and 
colleagues (10) evaluated the costs of such a screening 
and job placement strategy. They analyzed retrospective 
data from 2150 employees in a single automobile parts 
manufacturer. In this company, all new employees were 
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screened with EDS, but hiring decisions were not made 
based on this information. Using workers’ compensation 
claims data and information from the company about 
the costs associated with screening, Franzblau et al 
concluded that basing hiring decisions on the results of 
EDS would not have been cost-beneficial, as the cost of 
screening all new workers exceeded the cost of the CTS 
cases that might have been avoided. Furthermore, while 
workers with abnormal EDS at baseline had an increased 
risk of developing CTS, the majority of them remained 
asymptomatic. Most CTS cases actually occurred among 
workers with normal EDS at baseline. This study used 
data from a single employer, and the extent to which the 
results can be applied to other populations is not known.
The aim of our study was to construct a model pro-
viding a more generalized cost–benefit estimation of 
basing worker placement or hiring decisions on screen-
ing for CTS. In a hypothetical cohort of new employ-
ees, we compared the cost of screening all prospective 
employees for CTS and not hiring those with abnormal 
nerve conduction, versus a strategy of not screening for 
CTS. Variability in the results was assessed with both 
deterministic and probabilistic sensitivity analyses.
Methods
Model parameters
Baseline inputs to our model and the ranges for deter-
ministic sensitivity analyses are shown in table 1. Values 
were based on a review of the medical literature and 
expert opinion. The cost per case of CTS was based 
on published workers’ compensation claims data and 
chosen to be representative of a total claim cost to the 
employer or employer’s insurer for a case of CTS in the 
USA, including direct medical and disability costs (3, 
10, 11). The annual incidence of CTS in the entire work-
ing population (regardless of EDS results) was based on 
reported workers’ compensation claims (3, 10, 12–16). 
The prevalence of abnormal EDS and the relative risk of 
developing CTS among asymptomatic individuals with 
abnormal EDS were estimated from several studies in 
working populations (10, 17–23), as well as from the 
authors’ own unpublished data from an ongoing prospec-
tive study of CTS (data available from corresponding 
author). The cost of screening was based on data from 
local employers, occupational health practitioners, and 
the Franzblau et al study (10). The lower range of this 
cost estimate represents the lower screening cost that is 
associated with some portable EDS devices; the upper 
range is below the normal clinical charges for diagnostic 
EDS. The annual turnover rate incorporated a wide range 
of values to represent different industries and employ-
ment situations. The analysis was carried out from the 
perspective of the employer, since employers incur the 
costs of CTS attributed to work activities, and a screen-
ing program designed to reduce CTS in an employed 
workforce would be paid for by the employer. We chose 
a wide range of parameters for important inputs includ-
ing turnover rate and cost of a case of CTS, to make 
the model inclusive of different work settings and state 
compensation systems. We arbitrarily chose a five-year 
time horizon with a one-year time cycle. We modeled a 
working population of 10 000 workers, with continued 
hiring to replace workers who left employment. In the 
base case, future costs were not discounted; however the 
impact of discounting was tested in sensitivity analyses 
by varying the discount rate by up to 10%.
Accounting for the impact of assumptions on model 
outcomes
The validity of any decision analytic model, such as 
the one we constructed, is limited by the assumptions 
made regarding the model parameters. Therefore, we 
evaluated our model using sensitivity analyses to deter-
mine the extent to which these assumptions affected the 
outcome of the model. We conducted one- and two-way 
sensitivity analyses, in which one or two variables are 
taken through their entire respective ranges of potential 
values. For the six model parameters listed in table 1, we 
ran one-way sensitivity analyses for all model param-
eters individually, and two-way sensitivity analyses for 
all combinations of two parameters. 
Table 1. Inputs to the decision model, including the base model and the range of inputs used for sensitivity analysis. [EDS=electrodiagnostic 
studies; RR=relative risk]
 Carpal tunnel syndrome Electrodiagnostic studies
   Abnormal EDS 
   RR Prevalence
Base model 20 000 0.002 4 0.15 150 0.15
Range for sensitivity analysis 7500–30 000 0.001–0.02 3–5 0.05–0.25 120–250 0.0–0.5
 Cost Annual  Cost of  
 per case incidence  screening 
 (US$)   (US$)
  Annual 
   employee 
   turnover 
   rate
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Markov model
A Markov model is a mathematical method for estimat-
ing the costs and consequences of events that repeat in 
a cyclical manner, with each set of iterations referred to 
as a Markov cycle (24). In the context of this simulation, 
each Markov cycle was considered to be one year, and 
the events modeled over that year included the annual 
probability that someone would develop CTS, continue 
working without developing CTS, and leave work due 
to reasons other than CTS. The model was constructed 
as a dynamic cohort to maintain an average employee 
group of 10 000 workers for the hypothetical employer 
throughout the simulation period; employees who devel-
oped CTS or left employment during each cycle were 
replaced. We compared a strategy of pre-employment 
screening for abnormal nerve conduction among all new 
employees versus a no-screening strategy. Included in 
the model was the cost of screening additional work-
ers to compensate for those rejected from employ-
ment based on their EDS result. Our outcome was the 
expected incremental cost per employee position. The 
costs included in the model were the cost of (i) screening 
new employees and (ii) workers’ compensation claims 
for those who developed CTS. Our Markov model is 
illustrated in figure 1. We conducted probabilistic sen-
sitivity analysis using Monte Carlo simulations, with 
10 000 iterations varying all model inputs simultane-
ously through their full ranges as listed in table 1. Our 
decision analytic model was constructed using TreeAge 
Pro 2009 (TreeAge Software, Inc, Williamsport, MA, 
USA). Our analyses were guided by published prin-
ciples of good practice for decision analytic modeling 
in healthcare evaluations (25).
Results
Base model
The results of our base model comparing a strategy 
of pre-employment screening versus no screening are 
shown in table 2. The screening strategy resulted in the 
rejection of 3279 workers for employment, out of a total 




















Figure 1. Markov decision model for screening new hires using electrodiagnostic studies (EDS) versus a 
no-screening strategy. This illustrates the potential path taken by an individual worker. In each year, 
a worker could remain healthy and continue working, develop CTS and incur workers’ 
compensation costs, or leave the company due to reasons other than CTS. After the employee 
developed CTS, they could either keep working or leave the company. Each time a worker quits, is 
fired, or is not hired due to a “positive” or abnormal EDS, new job applicants must be screened or 
interviewed for employment.  
 
Figure 1. Markov decision model for screen-
ing new hires using electrodiagnostic studies 
(EDS) versus a no-screening strategy. This 
illustrates the potential path taken by an 
individual worker. In each year, a worker 
could remain healthy and continue working, 
develop carpal tunnel syndrome (CTS) and 
incur workers’ compensation costs, or leave 
the company due to reasons other than CTS. 
After the employee developed CTS, they could 
either keep working or leave the company. 
Each time a worker quits, is fired, or is not 
hired due to a “positive” or abnormal EDS, 
new job applicants must be screened or 
interviewed for employment. 
Table 2. Results comparing a strategy of pre-employment screening for carpal tunnel syndrome (CTS) versus no screening in hiring and 
maintaining a population of 10 000 workers for five years. 
 Outcome
 Workers Workers Cases of Costs of Cost of Total cost of  
 considered rejected for CTS all CTS cases screening all screening plus  
 for employment in the treated under new workers treatment of  
 employment due to employed workers’ (US$) CTS cases  
 (N) screening workforce compensation  in workforce 
  (N) (N) (US$)  (US$)
Screening strategy 24 336 3279 69 1 380 000 3 652 520 5 032 520
No screening strategy 20 691 – 100 2 000 000 – 2 000 000
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of 10 000 workers over five years. The screened work-
ers experienced 69 cases of CTS during the five-year 
period among those employed, versus 100 cases in 
the unscreened group. Workers’ compensation costs 
of CTS were substantially lower under the screening 
strategy (US$1 380 000 versus US$2 000 000). How-
ever, the cost of screening workers was substantial 
(US$3 652 520) and far outweighed the cost savings 
resulting from fewer cases of CTS among the screened 
employees. In our base case, the expected incremental 
cost under a screening program was US$303 greater per 
employee position when compared to the no-screening 
approach, as screening for CTS incurred more costs 
than were saved by the reduction in CTS cases among 
employees. Changing the discount rate had minimal 
impact on these findings. We also found the screening to 
be inefficient as 3279 workers were rejected for employ-
ment to avoid 31 additional cases of CTS (106 workers 
rejected for employment for each case prevented in the 
working population). 
Sensitivity analysis
In a one-way sensitivity analysis, only one parameter 
had a significant impact on the cost–benefit decision: the 
incidence of CTS among the working population. When 
this incidence was >0.012 (12 workers’ compensation 
cases per 1000 workers per year), a strategy of screening 
was favored. In a two-way sensitivity analysis, screen-
ing was favored only for combinations of the highest 
incidence rates and highest costs per case of CTS. In our 
probabilistic sensitivity analyses using 10 000 Monte 
Carlo simulations, a strategy of no screening was less 
expensive for the employer in 70% of the simulations. 
Discussion
Although screening for median nerve abnormalities at 
the time of job hiring is advocated and practiced as a 
strategy to prevent CTS in the workplace (4–6, 26), there 
has been little evaluation of this strategy in practice. The 
only formal evaluation of this practice was performed 
by Franzblau et al (10), who found that such screening 
was not cost-beneficial for the employer they studied. 
Our modeling used a wide range of possible values for 
the cost of a case of CTS, the likelihood of such a case, 
and the cost of screening. We found that a strategy of 
post-offer, pre-placement screening for CTS was not 
cost-beneficial in the majority of models tested. From 
the perspective of most individual employers, screening 
for CTS is unlikely to be cost-beneficial.
Although median nerve conduction abnormalities 
are important criteria for the diagnosis of CTS, most 
asymptomatic people with such abnormalities remain 
asymptomatic (10, 18–22). In the screening scenario we 
modeled, 3279 workers were rejected for employment 
over five years in order to avoid 31 cases of CTS for an 
employer. Of these 3279 workers, 56 (1.7%) went on to 
develop CTS. It is appropriate to ask how great a dif-
ference in the risk of future disease must exist between 
persons hired and persons not hired in an effort to reduce 
the burden of future disease. From a broader viewpoint, 
rejecting workers for employment at one employer prob-
ably does not reduce the societal burden of CTS in the 
total workforce. It is likely that rejected job applicants 
will seek employment with other employers, often per-
forming work with similar risk factors for CTS, and may 
still develop CTS despite being rejected for employment 
by one employer. Potential gain for employers must be 
weighed against societal costs and costs to individual 
workers, including discrimination and inappropriate 
referral for treatment (8, 10, 27). 
Our study had several limitations that may affect its 
conclusions. Decision models using different assump-
tions will arrive at different answers. We chose estimates 
of costs, prevalence of CTS, and increased risk of CTS 
associated with abnormalities of nerve conduction from 
a review of the relevant literature and conversations 
with clinical experts. We modeled screening from the 
viewpoint of the employer, since it is employers who 
make decisions regarding the use of screening among 
their workforce. This viewpoint does not account for 
a number of relevant social costs that pertain to the 
perspectives of individual workers or society at large. 
There may be additional, unaccounted for costs of 
screening to the employer; for example, the rejection 
of an otherwise qualified job candidate due to median 
nerve abnormality necessitates offering the position to a 
potentially less qualified candidate with normal median 
nerve conduction. Although our analysis suggests that 
pre-employment screening for CTS is not cost-beneficial 
to the majority of employers, our sensitivity analyses 
indicate that under some circumstances (high incidence 
rate of CTS and high cost per case) it could be cost-
beneficial for the employer. 
As pointed out by de Kort & van Dijk more than a 
decade ago (1), workplace screening policies are wide-
spread, though they have rarely been subject to formal 
analysis. Workplace screening policies are common in 
the United States, where they are used to screen for sus-
ceptibility to conditions such as low-back pain, upper-
extremity musculoskeletal disorders, allergies to specific 
compounds, and the ability to safely use a respirator. 
Available studies of pre-employment screening indicate 
that the yield of such practices is low. A study examining 
over 100 000 pre-employment medical examinations in 
the Netherlands found a low rate of employee rejection 
(0.6%), and little relationship between job demands and 
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the diagnoses that prompted rejection (28). The use of 
spirometry and physical examination were found to add 
little to the detection of relevant medical conditions for 
clearance to use a respirator (29). Although screening 
for musculoskeletal disorders is advocated as a way 
to reduce workers’ compensation costs (30), existing 
screening policies are rarely based on data showing 
appropriate diagnostic yield or cost–benefit outcome. 
In a systematic review of assessment for fitness for 
work, Serra et al (31) found general confusion about the 
decision-making process used to judge fitness for work 
and very scarce scientific evidence based on empirical 
data to support current practices. 
Concluding remarks
We conclude that a strategy of post-offer screening for 
CTS is not cost-beneficial to the majority of employers, 
and any such screening should be carefully evaluated for 
economic yield and social consequences before being 
implemented. The techniques of cost–benefit analysis 
are not widely used in the evaluation of occupational 
health and safety policies, but should be used more 
widely to guide rational practice.
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